The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
telephone:
01413304744
email:
Elizabeth.Thomson@glasgow.ac.uk
Clarice Pears Building, Level 5, 90 Byres Road, Glasgow, G12 8TB
Cleland, J. et al. (2024) Adjudication of hospitalizations and deaths in the IRONMAN Trial of intravenous iron for heart failure. Journal of the American College of Cardiology, 84(18), pp. 1704-1717. (doi: 10.1016/j.jacc.2024.08.052) (PMID:39443013) (PMCID:PMC11496827)
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)
Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)
Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)
Mccowan, C. , Thomson, E., Szmigielski, C. A., Kalra, D., Sullivan, F. M., Prokosch, H.-U., Dugas, M. and Ford, I. (2015) Using electronic health records to support clinical trials: a report on stakeholder engagement for EHR4CR. BioMed Research International, 2015, 707891. (doi: 10.1155/2015/707891) (PMID:26539523) (PMCID:PMC4619877)
Cleland, J. et al. (2024) Adjudication of hospitalizations and deaths in the IRONMAN Trial of intravenous iron for heart failure. Journal of the American College of Cardiology, 84(18), pp. 1704-1717. (doi: 10.1016/j.jacc.2024.08.052) (PMID:39443013) (PMCID:PMC11496827)
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)
Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)
Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)
Mccowan, C. , Thomson, E., Szmigielski, C. A., Kalra, D., Sullivan, F. M., Prokosch, H.-U., Dugas, M. and Ford, I. (2015) Using electronic health records to support clinical trials: a report on stakeholder engagement for EHR4CR. BioMed Research International, 2015, 707891. (doi: 10.1155/2015/707891) (PMID:26539523) (PMCID:PMC4619877)